Jennie Walgren
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Computational Drug Discovery Methods, Synthesis and biological activity, Cancer Mechanisms and Therapy, Microtubule and mitosis dynamics
Most-Cited Works
- → Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity(2005)320 cited
- → Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers(2015)305 cited
- → High glucose and insulin promoteO-GlcNAc modification of proteins, including α-tubulin(2003)157 cited
- → ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine(2019)104 cited
- → Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells(2015)84 cited
- → Application of proteomic technologies in the drug development process(2004)81 cited
- → Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy(2019)52 cited
- → Proteomics: Recent Applications and New Technologies(2006)49 cited
- → Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial(2025)40 cited
- → Effect of R(+)α-Lipoic acid on pyruvate metabolism and fatty acid oxidation in rat hepatocytes(2004)35 cited